Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. [electronic resource]
Producer: 20150623Description: E77-9 p. digitalISSN:- 1096-8652
- Age Factors
- Aged
- Antimetabolites, Antineoplastic -- therapeutic use
- Azacitidine -- analogs & derivatives
- DNA Modification Methylases -- antagonists & inhibitors
- Decitabine
- Female
- Genotype
- Humans
- Isocitrate Dehydrogenase -- genetics
- Leukemia, Myeloid, Acute -- diagnosis
- Male
- Mutation
- Odds Ratio
- Prognosis
- Remission Induction
- Retrospective Studies
- Sex Factors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.